Skip to content

Molecular Biology Study of Eczema with Spleen Yang Deficiency Syndrome in Dampness

Molecular Biology Study of Eczema with Spleen Yang Deficiency Syndrome in Dampness

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051446
Enrollment
Unknown
Registered
2021-09-23
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wet sores

Interventions

Eczema group:None
healthy control group:None

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Wet Sore Group: 1. The patients with dermatological eczema in our hospital are in line with the syndrome differentiation standard of eczema dampness blocking middle Jiao and spleen-yang deficiency in the "Traditional Chinese Medicine Disease Syndrome Diagnosis and Efficacy Standards"; 2. Aged 18 to 55 years, no gender restrictions, subjects signed a written informed consent to participate in this trial; 3. Currently not accompanied by sudden diarrhea, abdominal pain and other acute gastrointestinal inflammation; 4. No history of application of traditional Chinese medicine, antibiotics, antifungal and glucocorticoid drugs (except emollients) in the past 1 month. Healthy control group: 1. Age-matched health check-up population in our hospital; 2. The subjects signed the written informed consent form agreeing to participate in this trial.

Exclusion criteria

Exclusion criteria: Wet Sore Group: 1. Carry out systemic immunosuppressant, ultraviolet, biological agents and other treatments; 2. History of acute asthma attack, bone marrow transplantation or gene therapy, application of hormone maintenance therapy, etc.; 3. Combined with serious heart, lung, liver, kidney, gastrointestinal diseases; history of intestinal surgery or trauma; Healthy control group: 1. Combined with other allergic diseases, such as asthma, allergic rhinitis, hay fever, allergic conjunctivitis, urticaria; 2. Complicated infectious diseases; 3. Combined with severe heart, lung, liver, kidney, gastrointestinal diseases; history of intestinal surgery or trauma.

Design outcomes

Primary

MeasureTime frame
Skin lesion area;Th2 cell expression rate;

Secondary

MeasureTime frame
IL-4;IL-1;

Countries

China

Contacts

Public ContactWu Yalan

Guangzhou University of Chinese Medicine

wuyalan968825@163.com+86 18520264095

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026